Breaking News, Collaborations & Alliances

Rokote Laboratories Licenses Cevec’s Proprietary CAP Ad Technology

Gains non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Cevec Pharmaceuticals GmbH and Rokote Laboratories Finland Ltd have signed an agreement on the use of Cevec’s proprietary CAP Ad Technology for the manufacturing of vaccines in various indications.   Under the agreement, Cevec has granted Rokote Laboratories Finland Ltd non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections. Cevec in return is eligib...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters